[Ip-health] KEI Submission to Oregon on R&D Cost Transparency Provisions in SB 793

Zack Struver zack.struver at keionline.org
Wed Mar 8 14:24:08 PST 2017


Today, KEI submitted written testimony on SB 793 — a bill that is designed
to allow the Oregon Department of Consumer and Business Services to
investigate price increases for prescription drugs — in advance of a
hearing before the Oregon Senate Committee on Health Care at 1:00 P.M.
(PST) on March 9, 2017.

KEI asked the Committee to amend the bill to require more detailed
disclosure of the costs associated with research and development, including
per patient and per phase clinical trial costs, and to require that any
data collected in pursuit of an investigation under the act be made
available to the public.

Zack Struver, Communications and Research Associate
Knowledge Ecology International
zack.struver at keionline.org
Twitter: @zstruver <https://twitter.com/zstruver>
Office: +1 (202) 332-2670 Cell: +1 (914) 582-1428

More information about the Ip-health mailing list